Author

N. Packiriswamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Balakrishnan· 2 shared L. Zhang· 2 shared R. Narjari· 2 shared R. Vandergaast· 2 shared S. J. Russell· 2 shared A. Baum· 1 shared A. Garcia-Sastre· 1 shared C. A. Kyratsous· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Balakrishnan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.

M. A. Munoz Alia, R. A. Nace, B. Balakrishnan, L. Zhang, N. Packiriswamy, G. Singh, P. Warang, I. Mena, R. Narjari, R. Vandergaast, A. Garcia-Sastre, M. Schotsaert, S. J. Russell

This study develops a measles-based vaccine encoding SARS-CoV-2 spike glycoproteins that enhances neutralizing antibody responses against both omicron and historical variants.

mBio · Feb 14, 2024Peer-reviewedMicrobiology

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

K. W. Peng, T. Carey, P. Lech, R. Vandergaast, M. A. Munoz-Alia, N. Packiriswamy, C. Gnanadurai, K. Krotova, M. Tesfay, C. Ziegler, M. Haselton, K. Sevola, C. Lathrum, S. Reiter, R. Narjari, , S. J. Russell

This study develops an oral rhabdoviral vaccine that boosts SARS-CoV-2 immunity in nonhuman primates by enhancing viral tropism through G protein trans-complementation.

bioRxiv · Oct 16, 2021Immunology